Stem Cell Club — Header Component
⏳ Standard price $2,499 → $1,999 locked in for life during our current promotion. Book now →

Research Spotlight · Heart Failure

For 25 years, researchers have tried to fix failing hearts with stem cells. In 2026, two very different ideas made news: lab-grown heart muscle stitched onto the heart, and donor cells used to calm inflammation. Here is what the newest trials actually found, what the older trials taught the field the hard way, and where things stand right now.

By The Stem Cell Club Editorial Team November 4, 2026 12 min read

Here is a fact most people don't know about the heart. Once you're an adult, it barely makes new muscle.

Skin heals. Bone knits. The liver regrows. But when a heart attack kills a patch of heart muscle, the body fills the gap with scar. Scar doesn't squeeze. And over the years, the rest of the heart works harder to make up for it until it starts to fail.

So the idea of putting new cells into a damaged heart has pulled in some of the best researchers in medicine. It also pulled in a scandal, a long string of disappointing trials, and plenty of clinics happy to sell hope by the IV bag.

This post skips the sales pitch. It walks through the actual studies: how many people were in them, what they measured, and what happened. The story is more interesting than either the hype or the cynics suggest.

Key takeaways No stem cell therapy is FDA-approved for heart failure as of November 2026. The first wave of trials, mostly using a patient's own bone marrow cells, produced small or inconsistent results, and a major line of "cardiac stem cell" research was later found to rest on falsified data. The largest trial so far, DREAM-HF (565 patients), missed its primary goal, though some secondary and subgroup findings drew interest. In 2026, two small early trials of heart muscle grown from induced pluripotent stem (iPS) cells were published in the New England Journal of Medicine and Nature Medicine. Both reported early signals in about 20 patients each, along with real risks, including abnormal heart rhythms. A 40-patient placebo-controlled trial of umbilical cord MSCs found no difference in the main measure of heart pumping. This is a fast-moving, promising field. It is not a proven treatment.
0 stem cell therapies approved by the FDA for heart failure as of November 2026
565 patients in DREAM-HF, the largest heart failure cell therapy trial to date. It missed its primary goal
20 + 20 patients in the two 2026 iPS heart muscle trials combined. Early, small, and closely watched

Why Are Researchers Studying Stem Cells for Heart Failure?

Heart failure means the heart can't pump enough blood to meet the body's needs. It doesn't mean the heart has stopped. It is one of the most common reasons older adults end up in the hospital.

Today's treatments are good and getting better. Several classes of medicines, implanted devices, and procedures to open blocked arteries help people live longer. For the sickest patients, there are mechanical pumps called left ventricular assist devices (LVADs) and heart transplants.

But none of those treatments replace lost heart muscle. They help the remaining muscle work, protect it, or take over its job. That is the gap researchers want to fill.

There are two big ideas in the field, and it helps to keep them apart:

  • Replace the muscle. Grow new heart muscle cells in a lab and put them into or onto the heart, so there is more tissue that can actually contract. This is the idea behind the iPS cell trials.
  • Change the environment. Give cells such as MSCs that are not expected to become heart muscle, but that release signals which may reduce inflammation and support the tissue that's already there. This is the idea behind most MSC trials, including DREAM-HF.

Those are very different bets. A result for one tells you very little about the other.

What Happened to the First Wave of Heart Stem Cell Trials?

Starting in the early 2000s, dozens of trials injected patients' own bone marrow cells into the heart after a heart attack or in chronic heart failure. Many early, small studies reported encouraging changes. As the trials got bigger and better controlled, the benefits mostly shrank.

The clearest example is BAMI, published in the European Heart Journal in 2020. It was designed as a Phase 3 trial to see whether bone marrow cells infused into the heart artery after a heart attack would lower the death rate. It enrolled 375 patients, far fewer than planned. Death rates at two years were low in both groups (3.26% with cells, 3.82% without), and the authors wrote that the low enrollment and low event rates "preclude any meaningful group comparisons." In plain words: the biggest trial of that approach couldn't answer its own question.

Then there was the scandal. A prominent Harvard lab had published years of research claiming the heart contains its own stem cells, marked by a protein called c-kit, that can rebuild heart muscle. Other labs couldn't reproduce it. In 2018, Harvard Medical School and Brigham and Women's Hospital recommended retracting 31 papers from that lab, saying they included falsified or fabricated data.

That is a hard chapter. It is also the reason today's trials are held to a higher standard. The field didn't quit. It got more careful.

What Did the Large MSC Trials Find?

DREAM-HF: 565 patients, the largest trial yet

DREAM-HF tested rexlemestrocel-L, a donor bone marrow product made of mesenchymal precursor cells, developed by Mesoblast. Patients with chronic heart failure and reduced pumping function got a single injection of cells into the heart muscle through a catheter, or a sham procedure. It was randomized and double-blind. Results were published in the Journal of the American College of Cardiology in 2023.

The primary goal was to reduce repeat episodes of worsening heart failure. It did not. The rate was similar between groups (hazard ratio 1.17, p = 0.41). The secondary goals, including deaths, were also negative. The authors wrote it plainly: "The primary and secondary endpoints of the trial were negative."

What kept the program alive were other signals. In the cell group, heart pumping function (ejection fraction) rose more over 12 months, especially in patients with higher markers of inflammation. The risk of heart attack or stroke was 58% lower in the cell group across the analysis population of 537 patients. A follow-up analysis published in the European Journal of Heart Failure focused on patients with ischemic heart failure (caused by blocked arteries) and high inflammation, and reported larger reductions in those events.

Two cautions matter here. First, these were secondary and exploratory findings, and analyses chosen after the main result is known can't prove benefit. Second, several authors were Mesoblast employees or consultants, and the company funded the trial. That doesn't make the data wrong. It is something any careful reader should know.

SCIENCE: 133 patients, Europe

The SCIENCE trial, a European Phase 2 study published in 2023, injected donor fat-derived MSCs directly into the heart muscle of 133 people with chronic heart failure. It was double-blind and placebo-controlled.

The cells were safe, with no drug-related serious side effects over three years. But there was no difference from placebo in the primary measure of heart size, or in pumping function, walking distance, or quality of life. The authors concluded it "was not possible to improve the pre-defined endpoints."

CONCERT-HF: 125 patients, U.S.

CONCERT-HF was a Phase 2, double-blind, placebo-controlled trial funded by the National Heart, Lung, and Blood Institute. It tested patients' own bone marrow MSCs, their own c-kit positive heart cells, or both, in 125 people with heart failure after heart attacks. Results were published in 2021.

Heart pumping function, scar size, and walking distance did not change compared with placebo. Some clinical measures moved: major cardiac events were lower with the heart-derived cells, and quality-of-life scores improved with MSCs. The authors suggested the cells may work through signaling rather than by rebuilding muscle, and called for more research.

Why do heart cell trials keep producing mixed results?

  • Most cells don't stay. Studies have repeatedly found that only a small fraction of injected cells remain in the heart after the first days.
  • "Stem cells" means many different products. Bone marrow mixes, purified MSCs, fat-derived cells, heart-derived cells, and lab-grown heart muscle are not interchangeable.
  • Heart failure care keeps improving. Newer medicines lower event rates, so a cell therapy has to beat a moving target.
  • Secondary findings tempt everyone. When the main goal misses, a positive secondary result is a reason for the next trial, not a conclusion.

What Did the 2026 iPS Heart Muscle Trials Show?

This is where the newest excitement is. Instead of hoping donor cells send helpful signals, these teams grew actual heart muscle cells from induced pluripotent stem (iPS) cells, which are adult cells reprogrammed in the lab. The goal is to add muscle that beats. We covered the basics of iPS cells in our post on Japan's iPS approvals.

BioVAT-HF: a lab-grown heart muscle patch (NEJM, May 2026)

A German team grew sheets of engineered heart muscle from donor iPS cells and surgically attached them to the outside of the failing heart. They call it biologic ventricular assist tissue, or BioVAT. The open-label Phase 1-2 study was published in the New England Journal of Medicine in May 2026.

Twenty patients with severe heart failure (ejection fraction of 35% or less) were treated. All took immune-suppressing drugs to prevent rejection of the donor tissue. Sixteen got the highest dose. Of those, 12 had reached the planned 3-month check in this interim analysis.

At 3 months, the treated heart wall was thicker by an average of 4.5 mm. Ejection fraction rose by 3.9 percentage points. A quality-of-life score rose 6.7 points, which did not reach statistical significance (p = 0.06).

Now the other side. Three patients died during the study, from causes the report lists as vasoplegia (a dangerous drop in blood pressure), COVID-19, and a tear in the aorta. One patient later had a heart transplant. Immunosuppression had to be stopped in four patients, including one who developed bladder cancer. Every patient had at least one adverse event. There was no control group.

The authors called for longer follow-up and more trials. That is the honest read: a real signal that lab-grown heart muscle can be added to a human heart, in a small, very sick group, with serious open questions about safety and lasting benefit.

HEAL-CHF: iPS heart cells injected during bypass surgery (Nature Medicine, 2026)

A team in Nanjing, China, took a different route. Twenty patients with advanced heart failure who needed bypass surgery were randomized. Ten had donor iPS-derived heart muscle cells injected into the heart during their bypass. Ten had bypass alone. The trial was published in Nature Medicine in 2026.

The primary goal was safety. No sustained ventricular tachycardia, a dangerous fast heart rhythm, occurred in months 1 to 6, and no tumors were found at 12 months in either group. But in the first four weeks, all 10 patients who got cells developed an abnormal rhythm called accelerated idioventricular rhythm. Two had a fast ventricular rhythm that needed cardioversion (an electrical reset) and then resolved.

On the efficacy side, the cell group did better than bypass alone in walking distance, blood flow to the heart muscle, and how much the heart wall thickened with each beat. There was no significant difference in ejection fraction, heart size, scar size, symptom class, or quality of life at 12 months.

The authors wrote that future studies "will need to determine the risk-to-benefit ratio" because of the rhythm problems. Several authors work for or hold equity in HELP Therapeutics, the company that made the cells, which also helped fund the work.

What About Umbilical Cord MSCs for Heart Failure?

A lot of people searching this topic want to know about umbilical cord MSCs. There is now a placebo-controlled trial to look at.

PRIME-HFrEF, run at Shanghai East Hospital and published in Signal Transduction and Targeted Therapy in 2026, randomized 40 patients with heart failure and reduced ejection fraction. Half got three IV infusions of umbilical cord MSCs, six weeks apart. Half got placebo. It was double-blind, and patients were followed for a year.

Here is what it found:

  • Main pumping measure: Ejection fraction rose in both groups. The difference between groups was not significant. In fact, the placebo group's average rise was slightly larger.
  • Right side of the heart: The right ventricle got smaller (a good sign) in the cell group compared with placebo, a secondary finding.
  • Hospital and death: Death or a heart failure hospitalization occurred in 6 of 20 cell patients and 5 of 19 placebo patients. Not a significant difference. Two deaths occurred in the cell group and none in placebo; the investigators judged them more likely due to other causes.
  • A clotting signal: Patients who got cells had higher D-dimer levels, a blood marker linked to clotting. The authors suggested this may have blunted any benefit.

That's a careful, small, early trial. It doesn't show that IV cord MSCs help a failing heart pump better. It does give researchers specific things to study next.

How Do the Main Heart Failure Cell Therapy Trials Compare?

Trial Cells and delivery Design and size What it found
BAMI (2020) Patient's own bone marrow cells, into the heart artery after heart attack Randomized, open-label, 375 patients (fewer than planned) Too few events to draw conclusions
CONCERT-HF (2021) Own bone marrow MSCs and/or heart-derived cells, injected into heart Phase 2, placebo-controlled, 125 patients No change in pumping or scar; some clinical measures improved
DREAM-HF (2023) Donor mesenchymal precursor cells, injected into heart Randomized, sham-controlled, 565 patients Missed primary and secondary goals; fewer heart attacks and strokes (secondary)
SCIENCE (2023) Donor fat-derived MSCs, injected into heart Phase 2, placebo-controlled, 133 patients Safe; no improvement in any main measure
PRIME-HFrEF (2026) Donor umbilical cord MSCs, 3 IV infusions Placebo-controlled, 40 patients No difference in ejection fraction; right heart volumes improved; clotting marker rose
BioVAT-HF (2026) iPS-derived engineered heart muscle patch, surgery Phase 1-2, open-label, 20 patients Thicker heart wall and higher ejection fraction at 3 months in 12 evaluated; deaths and adverse events reported
HEAL-CHF (2026) iPS-derived heart muscle cells, injected during bypass Early-stage randomized, 20 patients Safety goal met; early rhythm problems in all treated; no ejection fraction difference

Is Stem Cell Therapy for Heart Failure FDA-Approved?

No. As of November 2026, the FDA has not approved any stem cell or cell therapy for heart failure. Every product in this post is investigational.

One program is moving toward a decision. In mid-2026, Mesoblast announced it had received a filing number from the FDA and requested a modular review of a Biologics License Application for rexlemestrocel-L. The proposed use is narrow: preventing life-threatening gastrointestinal bleeding tied to right heart failure in end-stage patients kept alive by an LVAD. In its October 2026 quarterly report, the company said the FDA confirmed the filing may proceed. That is a step in a review process. It is not an approval, and it would not cover heart failure in general.

Mesoblast's other cell product, Ryoncil, is the only MSC therapy the FDA has approved, for a complication of bone marrow transplants in children. We explain it in our Ryoncil explainer. And a different cell product made from heart tissue, deramiocel, is being studied for the heart muscle disease that comes with Duchenne muscular dystrophy; see our HOPE-3 post. For the bigger picture, read our guide to stem cell therapy and FDA approval.

What Are the Honest Objections?

  • The big trials missed. DREAM-HF, the largest trial, missed its primary goal. So did SCIENCE. That has to sit at the center of any honest summary.
  • The exciting 2026 results come from tiny studies. BioVAT-HF and HEAL-CHF had about 20 patients each. BioVAT-HF had no control group. Small studies often look better than the large trials that follow.
  • The new approaches carry new risks. Lab-grown heart muscle can cause rhythm problems, and donor tissue can require long-term immune suppression, which brings its own dangers.
  • The field has a credibility scar. The cardiac stem cell retractions are a reminder to look for independent replication, not just one lab's results.
  • Clinic settings aren't trials. Trials screen patients, control the product, and track side effects. Heart failure patients are fragile, and some trials have reported clotting changes and arrhythmias. Our overview of stem cell therapy side effects covers the general risks.

What Should Someone With Heart Failure Do With This Information?

We can't give medical advice, and we won't pretend to. But here is what the research itself points to.

Proven heart failure care comes first: the medicines your cardiologist prescribes, devices when they fit, and the lifestyle steps that go with them. Nothing in these trials suggests replacing any of that.

If you're curious about cell therapy for your heart, the legitimate path is a registered clinical trial. Search ClinicalTrials.gov for heart failure stem cell studies and bring what you find to your cardiologist. Real trials have a registration number, ethics approval, and usually a control group. They rarely charge participants.

Be wary of anyone who quotes you a success rate for heart failure, promises a stronger heart, or shows testimonials in place of published data. The trials above are the best evidence that exists, and none of them support that kind of promise.

Where The Stem Cell Club Fits

We are not part of any of these trials and have no connection to the companies or universities that ran them.

We offer umbilical cord Wharton's Jelly MSC options sourced from an FDA-registered U.S. lab. They are not the products tested in these trials, and these results do not apply to them. Lab registration covers facility and manufacturing standards. It is not FDA approval of a therapy. Our offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease, including heart failure, and we don't offer any heart procedure.

If you have heart failure, your cardiologist is the right first call. If you want an honest conversation about what regenerative research does and doesn't show, we're glad to have it. We keep a checklist of questions to ask any stem cell clinic, including us.

Frequently Asked Questions

Is there an FDA-approved stem cell therapy for heart failure?

No. As of November 2026, the FDA has not approved any stem cell or cell therapy for heart failure. Every product discussed here is investigational. Mesoblast has requested FDA review of rexlemestrocel-L for a narrow use in end-stage patients with a left ventricular assist device (preventing serious gastrointestinal bleeding), but that is a filing, not an approval.

Can stem cells repair a damaged heart?

That has not been shown in people. Researchers are testing two ideas: adding new heart muscle grown from induced pluripotent stem cells, and using cells such as MSCs to calm inflammation. Two 2026 trials of about 20 patients each reported early signals for lab-grown heart muscle, along with serious adverse events and rhythm problems. Larger, controlled trials are needed.

What did the DREAM-HF trial find?

DREAM-HF randomized 565 patients with chronic heart failure to a single heart injection of donor mesenchymal precursor cells or a sham procedure. It missed its primary goal of reducing repeat heart failure events (hazard ratio 1.17, p = 0.41), and its secondary goals were also negative. Exploratory analyses found fewer heart attacks and strokes in the cell group, especially in patients with high inflammation, which the company is now studying further.

What is BioVAT?

BioVAT, short for biologic ventricular assist tissue, is engineered heart muscle grown from donor induced pluripotent stem cells and attached to the outside of the heart during surgery. In a 20-patient open-label Phase 1-2 study published in the New England Journal of Medicine in 2026, the 12 patients evaluated at 3 months had a thicker heart wall and a 3.9-point rise in ejection fraction. Three patients died during the study, all patients had at least one adverse event, and there was no control group.

Are umbilical cord stem cells being studied for heart failure?

Yes. In the PRIME-HFrEF trial, published in 2026, 40 patients with heart failure were randomized to three IV infusions of umbilical cord MSCs or placebo. Ejection fraction rose in both groups with no significant difference between them. The cell group showed improved right ventricle volumes, a secondary finding, and higher levels of a clotting marker called D-dimer.

Is stem cell therapy for heart failure safe?

In controlled trials, many cell products have been reported as generally well tolerated, but the risks depend on the product and procedure. Lab-grown heart muscle cells caused early abnormal heart rhythms in a 2026 trial, donor tissue may require immune-suppressing drugs, and one cord MSC trial found a rise in a clotting marker. Trials screen and monitor patients closely, and that oversight is not guaranteed outside a trial.

How can I find a legitimate heart failure stem cell trial?

Search ClinicalTrials.gov for heart failure cell therapy studies and review what you find with your cardiologist. Legitimate trials have a registration number, ethics approval, and usually a control group, and they rarely charge participants.

Does The Stem Cell Club offer stem cell therapy for heart failure?

No. The Stem Cell Club is not affiliated with any of the trials described here, and their results do not apply to our services. Our umbilical cord Wharton's Jelly MSC offerings are different products from those studied, we do not offer any heart procedure, and our offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease, including heart failure.

Want a Straight Answer About Regenerative Options?

Our free consultation is honest about what the research shows and what it doesn't. If something isn't a fit for you, we'll say so.

Schedule a Free Consultation → Or call (435) 281-2999

Educational content only, not medical advice. Individual results vary. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. FDA registration of the source lab pertains to facility and manufacturing standards only and does not constitute FDA approval. This article discusses investigational products in published studies and registered clinical trials. The Stem Cell Club is not affiliated with these studies, and their findings do not apply to our services. If you have chest pain, sudden shortness of breath, or fainting, call 911. Talk with your doctor before starting or changing any treatment.

BioVAT-HF: Zimmermann WH, Ensminger S, Kutschka I, et al. Stem-cell-derived biologic ventricular assist tissue in heart failure. N Engl J Med. 2026;394(20):1991–2001. doi:10.1056/NEJMoa2513525. PMID 42202318. NCT04396899.

HEAL-CHF: Zhang H, Menasché P, Fan J, et al. Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial. Nat Med. 2026;32(9):3331–3338. doi:10.1038/s41591-026-04605-1. PMID 42618633. NCT03763136.

PRIME-HFrEF: Han W, Jiao Y, Chen W, et al. PRIME-HFrEF trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure. Signal Transduct Target Ther. 2026;11. doi:10.1038/s41392-026-02678-5. PMID 41888108. NCT04992832.

DREAM-HF: Perin EC, Borow KM, Henry TD, et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure. J Am Coll Cardiol. 2023;81(9):849–863. doi:10.1016/j.jacc.2022.11.061. PMID 36858705. Perin EC, Borow KM, Henry TD, et al. Mesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation: DREAM-HF. Eur J Heart Fail. 2025;27(12):3288–3296. doi:10.1002/ejhf.3522. PMID 39593178.

SCIENCE: Qayyum AA, van Klarenbosch B, Frljak S, et al. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction: the SCIENCE trial. Eur J Heart Fail. 2023;25(4):576–587. doi:10.1002/ejhf.2772. PMID 36644821.

CONCERT-HF: Bolli R, Mitrani RD, Hare JM, et al. A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021;23(4):661–674. doi:10.1002/ejhf.2178. PMID 33811444.

BAMI: Mathur A, Fernández-Avilés F, Bartunek J, et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial. Eur Heart J. 2020;41(38):3702–3710. doi:10.1093/eurheartj/ehaa651. PMID 32860406.

Regulatory and context: Mesoblast, BLA filing number and modular review request for rexlemestrocel-L, June 30, 2026; Mesoblast, activity report for quarter ended September 30, 2026. Retraction Watch, Harvard and the Brigham recommend 31 retractions for cardiac stem cell work, October 14, 2018.